Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy

BACKGROUND: Adjuvant anti-PD1 treatment improves relapse-free survival (RFS) but has not been shown to improve overall survival (OS) in melanoma and is associated with risks of immune-related adverse events (irAEs), some permanent. We identified factors patients consider in deciding whether to under...

Descripción completa

Detalles Bibliográficos
Autores principales: Atkinson, Thomas M, Hay, Jennifer L, Young Kim, Soo, Schofield, Elizabeth, Postow, Michael A, Momtaz, Parisa, Warner, Allison Betof, Shoushtari, Alexander N, Callahan, Margaret K, Wolchok, Jedd D, Li, Yuelin, Chapman, Paul B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Melanoma and Cutaneous Malignancies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078893/
https://www.ncbi.nlm.nih.gov/pubmed/36745014
http://dx.doi.org/10.1093/oncolo/oyac266

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078893/
https://www.ncbi.nlm.nih.gov/pubmed/36745014
http://dx.doi.org/10.1093/oncolo/oyac266

Ejemplares similares